~~<i id='4CDCF8980F'><strike id='4CDCF8980F'><tt id='4CDCF8980F'><pre id='4CDCF8980F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

hotspot

author：hotspot 2025-09-05 11:22:41 - browse：35

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Elizabeth Holmes banned from government health programs

leisure time

explore

leisure time

entertainment

Wikipedia

FormerNIHdirectorFrancisCollinsnowservesasWhiteHousescienceadviserMattRourke/APFormerNIHdirectorandc

WSS

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Medicare proceeds with plan to claw back hospital funds

Research misconduct: Proposed new rules face resistance

All of Us, NIH's precision medicine initiative, gets a big boost

The surgeon had a dilemma only a Nazi medical text could resolve

Parkinson’s finding may lead to tests and, someday, treatments

entertainment

hotspot

leisure time

Drug repurposing or repositioning? The language matters

Francis Collins on trust in science and how Covid communications failed

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Malaria cases in Florida and Texas: Here’s what you need to know

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Peter Hotez and the public health issue of online harassment

Research misconduct: Proposed new rules face resistance

Medicare details structure of new drug price negotiation program

Humana cuts profit projections as Medicare Advantage costs soar

leisure time

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Eli Lilly, Pfizer, and others want in on the online prescription market

Gene therapy’s promise and the high cost of hope

EU regulator recommends expanding Mounjaro approval to obesity

EU regulator recommends expanding Mounjaro approval to obesity

NIH director takes cautious approach to Biden drug pricing priority

explore

leisure time

entertainment

Wikipedia